Sample of Keynote Speakers and their Case Studies
Global Internal Benchmark for key HR Metrics. Key HR Metrics are aggregated and shared globally between different regions so each region can compare their own results with others within Sony. This is a good use case of how own data is utilised and leveraged in a global scale.
Global Internal Benchmark for key HR Metrics. Key HR Metrics are aggregated and shared globally between different regions so each region can compare their own results with others within Sony. This is a good use case of how own data is utilised and leveraged in a global scale.
Global Internal Benchmark for key HR Metrics. Key HR Metrics are aggregated and shared globally between different regions so each region can compare their own results with others within Sony. This is a good use case of how own data is utilised and leveraged in a global scale.
This presentation aims to emphasise the challenges of signal detection and risk assessments within the Oncology Therapeutic Area. In addition, it provides some useful insights on how to address some of the main challenges in this landscape.
COVID-19 pandemic started in late 2019 in China, expanding worldwide rapidly in early 2020. It resulted in 7 mln deaths. It became a novel challenge to the pharmacovigilance system worldwide for the whole pharma industry, particularly those parties that introduced vaccines against COVID-19. The development of vaccines and the unprecedented volume of ISRs reported in a short period of time after mass vaccination programmes started resulted in various types of challenges that required new ways of managing data, risk, reporting, controls and application of new technologies. The pandemic provided lessons learned that impacted the future of effective pharmacovigilance systems.
This presentation aims to emphasise the challenges of signal detection and risk assessments within the Oncology Therapeutic Area. In addition, it provides some useful insights on how to address some of the main challenges in this landscape.
COVID-19 pandemic started in late 2019 in China, expanding worldwide rapidly in early 2020. It resulted in 7 mln deaths. It became a novel challenge to the pharmacovigilance system worldwide for the whole pharma industry, particularly those parties that introduced vaccines against COVID-19. The development of vaccines and the unprecedented volume of ISRs reported in a short period of time after mass vaccination programmes started resulted in various types of challenges that required new ways of managing data, risk, reporting, controls and application of new technologies. The pandemic provided lessons learned that impacted the future of effective pharmacovigilance systems.
This presentation aims to emphasise the challenges of signal detection and risk assessments within the Oncology Therapeutic Area. In addition, it provides some useful insights on how to address some of the main challenges in this landscape.
COVID-19 pandemic started in late 2019 in China, expanding worldwide rapidly in early 2020. It resulted in 7 mln deaths. It became a novel challenge to the pharmacovigilance system worldwide for the whole pharma industry, particularly those parties that introduced vaccines against COVID-19. The development of vaccines and the unprecedented volume of ISRs reported in a short period of time after mass vaccination programmes started resulted in various types of challenges that required new ways of managing data, risk, reporting, controls and application of new technologies. The pandemic provided lessons learned that impacted the future of effective pharmacovigilance systems.